Antimicrobial resistance in gonorrhea: The influence of epidemiologic and laboratory surveillance data on treatment guidelines: Alberta, Canada 2001-2007

Sexually Transmitted Diseases

Volumn 36, Issue 10, 2009, Pages 665-669

  Singh, Ameeta E ^a   Plitt, Sabrina ^b   Boyington, Curtiss ^b   Sutherland, Karen ^b   Lovgren, Marguerite ^b   Tilley, Peter ^b   Read, Ron ^b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN G; SPECTINOMYCIN; TETRACYCLINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CANADA; DRUG INDICATION; EPIDEMIOLOGICAL DATA; FEMALE; GONORRHEA; HEALTH SURVEY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PENICILLIN ALLERGY; PRACTICE GUIDELINE; SINGLE DRUG DOSE;

ADULT; CEFIXIME; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MALE; NEISSERIA GONORRHOEAE; PRACTICE GUIDELINES AS TOPIC; RISK-TAKING;

EID: 70350510208     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181aad9df     Document Type: Article

References (24)

1. Hook EW III, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling PF, Mardh PA, et al., ed. Sexually Transmitted Diseases, 3rd ed. New York, NY: McGraw-Hill, 1999: chap 32
2. Public Health Agency of Canada. Reported Cases of Notifiable STI1 From January 1 to December 31, 2006 and January 1 to December 31, 2007 and Corresponding Rates for January 1 to December 31, 2006 and 2007. Public Health Agency of Canada.
3. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44(suppl 3):S84-S101.
4. Tapsall J. Antimicrobial Resistance in Neisseria gonorrhoeae. Geneva, Switzerland: World Health Organization, 2001.
5. Tapsall JW. Antibiotic resistance in Neisseria gonorrhoeae. Clin Infect Dis 2005; 41(suppl 4):S263-S268.
6. Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007; 147:81-88.
7. Ota KV, Jamieson F, Fisman DF, et al. Prevalence of and risk factors for quinolone resistant Neisseria gonorrhea infection in Ontario. CMAJ 2009; 287-290.
8. Mann J, Kropp R, Wong T, et al. Gonorrhea treatment guidelines in Canada: 2004 update. CMAJ 2004; 171:1345-1346.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. Wayne PA: CLSI 2007.
10. Public Health Agency of Canada. Canadian Guidelines for Sexually Transmitted Infections, 2006. Available at: http://www.phac-aspc.gc. ca/std-mts/sti-2006/pdf/Guidelines-Eng-complete-06-26-08.pdf. Accessed March 25, 2009.
11. Alberta Treatment Guidelines for STI, 2008. Available at: http:// www.health.alberta.ca/documents/STI-Treatment-Guidelines-2008.pdf. Accessed on March 25, 2009.
12. Centers for Disease Control and Prevention (CDC). Update to CDC?s sexually transmitted diseases treatment guidelines, 2006: Fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332-336.
13. Singh AE, Tyrell G, Chui L, et al. Comparison of the Cobas Amplicor (Roche) PCR Assay With Culture for N. gonorrhoeae Under Unique Clinical Conditions. Ottawa, Canada: International Society for STD Research, 2003:27-30.
14. Public Health Agency of Canada. EpiUpdate: ciprofloxacin resistance to Neisseria gonorrhoeae in Canada, 2006. Available at: http://www.phac-aspc.gc.ca/ sti-its-surv-epi/ciprofloxacin-e.html.
15. WHO Western Pacific Gonococccal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific region, 2006. Commun Dis Intell 2008; 32; 48-51.
16. Tapsall JW, Limnios EA, Murphy D. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997-2006. J Antimicrob Chemother 2008; 61:150-155.
17. Giles JA, Falconio J, Yuenger JD, et al. Quinolone resistance-determining region mutations and por type of Neisseria gonorrhoeae isolates: Resistance surveillance and typing by molecular methodologies. J Infect Dis 2004; 189:2085-2093.
18. Lundback D, Fredlund H, Berglund T, et al. Molecular epidemiology of Neisseria gonorrhoeae: identification of the first presumed Swedish transmission chain of an azithromycin-resistant strain. APMIS 2006; 114:67-71.
19. Ng LK, Sawatzky P, Martin IE, et al. Characterization of cipro-floxacin resistance in Neisseria gonorrhoeae isolates in Canada. Sex Transm Dis 2002; 29:780-788.
20. Yong D, Kim TS, Choi JR, et al. Epidemiological characteristics and molecular basis of fluoroquinolone-resistant Neisseria gonorrhoeae strains isolated in Korea and nearby countries. J Antimicrob Chemother 2004; 54:451-455.
21. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275-1277.
22. Wang SA, Lee MV, O'Connor N, et al. Multidrug-resistant Neisseria gonorrhoeae with decreased susceptibility to ce-fixime-Hawaii, 2001. Clin Infect Dis 2003; 37:849-852.
23. CDC. Availability of cefixime 400 mg tablets-United States, April 2008. MWR Morb Mortal Wkly Rep 2008; 57; 435.
24. Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: Some possible remedies. Expert Rev Anti Infect Ther 2006; 4:619-628.